Nektar Therapeutics (NKTR) - Get in under right conditionsCompany info:
Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−8.425 CHF
−108.04 M CHF
89.39 M CHF
11.96 M
About Nektar Therapeutics
Sector
Industry
CEO
Howard W. Robin
Website
Headquarters
San Francisco
Founded
1990
FIGI
BBG00LVF05P6
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
NKTR High Tight Flag- Pre-Earnings High Flyer LONGNKTR is due for earnings on August 8th. The price from the opening bell on the 7th
pump nearly 100% to over $1.00 and then faded by a couple of cents.
The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity
action into a high tight type bull falg which is often considered t
monitor its daily price action to bottom fish itBased on 6 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $2.75 with a high forecast of $6.00 and a low forecast of $1.00. The average price target represents a 308.07% change from the last price of $0.67.
Nektar Therapeutics (NASDAQ: $NKTR) Ready To Kick Cancer's Azz🦵Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3
NKTR was a top gainer, rising +40.26%. Expect Uptrend reversalNektar Therapeutics (NKTR, $22.82) was one of top quarterly gainers, jumping +40.26% to $22.82 per share. My A.I.dvisor analyzed 169 stocks in the Pharmaceuticals: Major Industry over the last three months, and discovered that 156 of them (92.52%) charted an Uptrend while 13 of them (7.48%) trended
Nektar is reaching fair valueNektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance).
The 19% jump is making Nektar trading around its fair value. Like
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange NEKTAR THERAPEUTIC stocks are traded under the ticker NKTR.
We've gathered analysts' opinions on NEKTAR THERAPEUTIC future price: according to them, NKTR price has a max estimate of 85.62 CHF and a min estimate of 24.46 CHF. Watch NKTR chart and read a more detailed NEKTAR THERAPEUTIC stock forecast: see what analysts think of NEKTAR THERAPEUTIC and suggest that you do with its stocks.
Yes, you can track NEKTAR THERAPEUTIC financials in yearly and quarterly reports right on TradingView.
NEKTAR THERAPEUTIC is going to release the next earnings report on Aug 7, 2025. Keep track of upcoming events with our Earnings Calendar.
NKTR earnings for the last quarter are −3.19 CHF per share, whereas the estimation was −2.27 CHF resulting in a −40.39% surprise. The estimated earnings for the next quarter are −2.41 CHF per share. See more details about NEKTAR THERAPEUTIC earnings.
NEKTAR THERAPEUTIC revenue for the last quarter amounts to 9.26 M CHF, despite the estimated figure of 13.59 M CHF. In the next quarter, revenue is expected to reach 7.69 M CHF.
NKTR net income for the last quarter is −45.04 M CHF, while the quarter before that showed 6.59 M CHF of net income which accounts for −783.05% change. Track more NEKTAR THERAPEUTIC financial stats to get the full picture.
No, NKTR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 15, 2025, the company has 61 employees. See our rating of the largest employees — is NEKTAR THERAPEUTIC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEKTAR THERAPEUTIC EBITDA is −120.94 M CHF, and current EBITDA margin is −130.78%. See more stats in NEKTAR THERAPEUTIC financial statements.
Like other stocks, NKTR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEKTAR THERAPEUTIC stock right from TradingView charts — choose your broker and connect to your account.